Lannum to leave top IR role at Mallinckrodt

Mar 02, 2018
Award-winning head of investor strategy leaving company for personal reasons
Cole Lannum, senior vice president of investor strategy at Mallinckrodt Pharmaceuticals, is leaving the company due to personal reasons, the company has confirmed. ‘Cole is with us for some weeks in a transitional period,’ a company spokesperson tells IR Magazine.

Content Preview

to continue reading

  • Unlimited news online
  • Newsletter
Sign up to get stories direct to your inbox
logo-black logo-black